(NASDAQ: OLMA) Olema Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Olema Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast OLMA's revenue for 2026 to be $1,539,478,733, with the lowest OLMA revenue forecast at $1,539,478,733, and the highest OLMA revenue forecast at $1,539,478,733. On average, 2 Wall Street analysts forecast OLMA's revenue for 2027 to be $2,496,350,291, with the lowest OLMA revenue forecast at $1,703,689,797, and the highest OLMA revenue forecast at $3,289,010,785.
In 2028, OLMA is forecast to generate $5,391,596,628 in revenue, with the lowest revenue forecast at $5,391,596,628 and the highest revenue forecast at $5,391,596,628.